J&J to start clinical trial for COVID-19 vaccine in July

By The Science Advisory Board staff writers

June 10, 2020 -- Johnson & Johnson is accelerating its investigational SARS-CoV-2 vaccine candidate, Ad26.COV2-S, recombinant, with the initiation of a phase I/IIA clinical trial in late July.

The trial was scheduled to begin in September; however, based on the strength of preclinical data and discussions with regulatory authorities, the company has been able to accelerate the clinical development timeline.

The randomized, double-blind, placebo-controlled phase I/IIA trial will evaluate safety, response to vaccination, and immunogenicity of the vaccine candidate in 1,045 healthy adults 18 to 55 years of age, and in adults over 65 years of age. The study will be conducted in the U.S. and Belgium.

Johnson & Johnson is in discussions with the U.S. National Institute of Allergy and Infectious Diseases about the start date of the phase III clinical trial for the vaccine candidate, pending the positive outcome of phase I studies and proper regulatory approvals.

Meanwhile, Johnson & Johnson continues to ramp up manufacturing capacity in partnership with global collaborators to meet its goal of supplying over 1 billion doses globally by 2021.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here